Zynerba launches the Phase 2 trial of its Zygel CBD gel to treat 22q genetic condition - Proactive Investors USA & Canada

Zynerba launches the Phase 2 trial of its Zygel CBD gel to treat 22q genetic condition  Proactive Investors USA & Canada

Zynerba Pharmaceuticals (NASDAQ:ZYNE) - The disorder is caused by a small missing piece of the 22nd chromosome that can affect every system in the body.